menu
    • menu
    [{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"||Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ The Gamaleya National Center of Epidemiology and Microbiology","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ The Gamaleya National Center of Epidemiology and Microbiology","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ The Gamaleya National Center of Epidemiology and Microbiology","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ The Gamaleya National Center of Epidemiology and Microbiology","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ The Gamaleya National Center of Epidemiology and Microbiology","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Russian Direct Investment Fund"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac Lyo","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rAd26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rAd26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by The Gamaleya National Center of Epidemiology and Microbiology

    Menu

    The Gamaleya National Center of Epidemiology and Microbiology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            The Gamaleya National Center of Epidemiology and Microbiology

                            Russia arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Russian Direct Investment Fund

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sputnik V Demonstrates Strong Protection Against Omicron Variant, With Over 2 Times Higher Virus Neutralizing ...

                            Details : Sputnik V (Gam-COVID-Vac), shows significantly smaller (2.6 times) reduction of virus-neutralizing activity against Omicron as compared to the reference Wuhan variant than Pfizer vaccine (8.1-fold reduction for Sputnik V in contrast to 21.4-fold reductio...

                            Product Name : Sputnik V

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 20, 2022

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Russian Direct Investment Fund

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The Gamaleya National Center of Epidemiology and Microbiology

                            Russia arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rAd26

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open, Non-Randomised, Phase 1/2 Trial on The Safety, Tolerability, and Immunogenicity of Single-Dose Vaccin...

                            Details : The trial with involvement of 6000 participants would help to further investigate whether single-dose “Sputnik Light” vaccine could be a good choice for revaccination providing effective protection from SARS-CoV-2 infection in persons with pre-existi...

                            Product Name : Sputnik Light

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 02, 2021

                            Lead Product(s) : rAd26

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            The Gamaleya National Center of Epidemiology and Microbiology

                            Russia arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rAd26

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Dose Vaccine, Sputnik Light, Authorized for Use in Russia

                            Details : Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V, the world’s first registered vaccine against coronavirus.

                            Product Name : Sputnik Light

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 06, 2021

                            Lead Product(s) : rAd26

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            The Gamaleya National Center of Epidemiology and Microbiology

                            Russia arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sputnik V Demonstrates 97.6% Efficacy According to Analysis of Data from 3.8 Million Vaccinated Persons in Rus...

                            Details : Sputnik V vaccine demonstrated efficacy of 97.6%, based on the analysis of data on the infection rate of coronavirus among those in Russia vaccinated with both components of Sputnik V.

                            Product Name : Sputnik V

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 19, 2021

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            The Gamaleya National Center of Epidemiology and Microbiology

                            Russia arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EMA Starts Rolling Review of the Sputnik V COVID-19 Vaccine Share

                            Details : These study indicate that Sputnik V triggers the production of antibodies and immune cells that target the SARS-CoV-2 coronavirus and may help protect against COVID-19.

                            Product Name : Sputnik V

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 04, 2021

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            The Gamaleya National Center of Epidemiology and Microbiology

                            Russia arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Dr. Reddy\'s Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr Reddy’s is Pleased to Share that Sputnik V Showed Strong Efficacy, Immunogenicity and Safety Results in t...

                            Details : In an interim analysis of a Phase III clinical trial, Sputnik V showed strong efficacy, immunogenicity and safety results. Efficacy of Sputnik V against COVID-19 was reported at 91.6%.

                            Product Name : Sputnik V

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 02, 2021

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Dr. Reddy\'s Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            The Gamaleya National Center of Epidemiology and Microbiology

                            Russia arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UAE Starts Trials of Russia's Sputnik V Coronavirus Vaccine as Cases Rise

                            Details : Abu Dhabi has started Phase III clinical trials of Russia’s Sputnik V COVID-19 vaccine amid a surge in infections in the United Arab Emirates. Two doses of the vaccine will be given, 20 days apart, to volunteers.

                            Product Name : Sputnik V

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 07, 2021

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            The Gamaleya National Center of Epidemiology and Microbiology

                            Russia arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Russia's Sputnik Vaccine Applies for Phase 3 Study in Brazil

                            Details : The Sputnik vaccine is being developed by Moscow's Gamaleya Research Institute and marketed by the Russian Direct Investment Fund (RDIF). Brazilian partner Uniao Quimica, a pharmaceutical company, entered the request with Anvisa.

                            Product Name : Sputnik V

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 30, 2020

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            The Gamaleya National Center of Epidemiology and Microbiology

                            Russia arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Russian Direct Investment Fund

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Argentina has Registered the Sputnik V Vaccine Based on Russian Clinical Trial Data

                            Details : Registering the Sputnik V vaccine based on the data from clinical trials in Russia confirms ANMAT’s high confidence in Russian regulatory standards.

                            Product Name : Sputnik V

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 23, 2020

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Russian Direct Investment Fund

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            The Gamaleya National Center of Epidemiology and Microbiology

                            Russia arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Russian Direct Investment Fund

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RDIF Confirms Sputnik V COVID Vaccine’s Efficacy

                            Details : The Russian Direct Investment Fund (RDIF) has confirmed efficacy of over 90% for the Sputnik V vaccine. The Sputnik V vaccine efficacy against severe cases of coronavirus was 100%.

                            Product Name : Sputnik V

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 14, 2020

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Russian Direct Investment Fund

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth